| |
| |
|
| Insider
Information: |
Cline Christopher R. |
| Relationship: |
|
| City: |
San Diego |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
1 |
|
| Direct
Shares |
70,849 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$449,183 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
70,849 |
|
|
| Total
Value |
$449,183 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
|
|
| Stock
price went down : |
|
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Travere Therapeutics, Inc |
TVTX |
|
2024-04-11 |
70,849 |
2022-09-01 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
12 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| TVTX |
Travere Therapeutics, Inc |
CHIEF FINANCIAL OFFICER |
• – – |
2024-04-11 |
4 |
S |
$6.74 |
$364 |
D/D |
(54) |
70,849 |
0 |
% |
|
| TVTX |
Travere Therapeutics, Inc |
CHIEF FINANCIAL OFFICER |
• – – |
2024-02-01 |
4 |
S |
$8.53 |
$32,573 |
D/D |
(3,818) |
70,903 |
0 |
% |
|
| TVTX |
Travere Therapeutics, Inc |
CHIEF FINANCIAL OFFICER |
• – – |
2024-01-31 |
4 |
A |
$0.00 |
$0 |
D/D |
25,000 |
74,721 |
0 |
- |
|
| TVTX |
Travere Therapeutics, Inc |
CHIEF FINANCIAL OFFICER |
• – – |
2024-01-23 |
4 |
S |
$9.07 |
$7,735 |
D/D |
(853) |
49,721 |
0 |
% |
|
| TVTX |
Travere Therapeutics, Inc |
Chief Financial Officer |
• – – |
2023-09-05 |
4 |
S |
$14.71 |
$6,723 |
D/D |
(457) |
50,574 |
0 |
% |
|
| TVTX |
Travere Therapeutics, Inc |
Chief Financial Officer |
• – – |
2023-05-10 |
4 |
S |
$16.59 |
$7,548 |
D/D |
(455) |
51,031 |
0 |
% |
|
| TVTX |
Travere Therapeutics, Inc |
Chief Financial Officer |
• – – |
2023-04-11 |
4 |
S |
$21.49 |
$1,010 |
D/D |
(47) |
51,486 |
0 |
% |
|
| TVTX |
Travere Therapeutics, Inc |
Chief Financial Officer |
• – – |
2023-02-01 |
4 |
S |
$21.75 |
$34,542 |
D/D |
(1,588) |
51,533 |
0 |
% |
|
| TVTX |
Travere Therapeutics, Inc |
Chief Financial Officer |
• – – |
2023-01-31 |
4 |
A |
$0.00 |
$0 |
D/D |
20,250 |
53,121 |
0 |
- |
|
| TVTX |
Travere Therapeutics, Inc |
Chief Financial Officer |
• – – |
2023-01-24 |
4 |
S |
$21.90 |
$18,663 |
D/D |
(852) |
32,871 |
0 |
% |
|
| TVTX |
Travere Therapeutics, Inc |
Chief Financial OfficerOfficer |
• – – |
2022-09-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
28,723 |
|
% |
|
| TVTX |
Travere Therapeutics, Inc |
Chief Financial Officer |
• – – |
2022-09-01 |
4 |
A |
$0.00 |
$0 |
D/D |
5,000 |
33,723 |
0 |
- |
|
12 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
